U.S. markets closed
  • S&P 500

    3,941.48
    -32.27 (-0.81%)
     
  • Dow 30

    31,928.62
    +48.38 (+0.15%)
     
  • Nasdaq

    11,264.45
    -270.83 (-2.35%)
     
  • Russell 2000

    1,764.83
    -27.94 (-1.56%)
     
  • Crude Oil

    110.67
    +0.90 (+0.82%)
     
  • Gold

    1,865.00
    -0.40 (-0.02%)
     
  • Silver

    22.11
    +0.05 (+0.21%)
     
  • EUR/USD

    1.0735
    +0.0039 (+0.36%)
     
  • 10-Yr Bond

    2.7600
    -0.0990 (-3.46%)
     
  • GBP/USD

    1.2550
    -0.0038 (-0.30%)
     
  • USD/JPY

    126.8800
    -1.0080 (-0.79%)
     
  • BTC-USD

    29,564.11
    +406.08 (+1.39%)
     
  • CMC Crypto 200

    655.31
    -0.52 (-0.08%)
     
  • FTSE 100

    7,484.35
    -29.09 (-0.39%)
     
  • Nikkei 225

    26,748.14
    -253.38 (-0.94%)
     

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a report on gov.ie, a central portal for government services and information.

  • The plant itself will employ more than 300 once it's complete. In the meantime, Lilly plans to enlist some 500 temporary workers for the facility build.

  • The Limerick plant will boost Lilly's manufacturing network for biologic active ingredients, help meet "increased demand for existing Lilly products," and extend the geographic reach of the company's clinical pipeline.

  • Lilly specifically singled out its "promising" Alzheimer's portfolio on the last point.

  • In a recent interview, Lilly could launch Alzheimer's hopeful donanemab toward the end of 2022, Anat Ashkenazi, Lilly's chief commercial officer, said.

  • The anti-amyloid antibody, which would rival Biogen Inc's controversial Aduhelm (aducanumab), is up for accelerated approval. Lilly expects to complete its rolling FDA submission by the end of Q1 FY22.

  • Related: Lilly's Donanemab Lowers Alzheimer's-Associated Biomarkers In Patients With Early Disease.

  • The facility is expected to start the production of active pharmaceutical ingredients in 2022.

  • Lilly will submit a planning application with Limerick City and County Council in the next few weeks to win approval for the project.

  • Price Action: LLY shares are up 1.82% at $241.07 during the market session on the last check Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.